Tokyo Tape
Sign in
← Kohjin Bio

Annual report

177A.TEDINET S100TX40
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 120
MetricValuePeriodScopeSource row
Revenue¥4.8bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥4.7bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥3.9bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Operating income¥597m2023-04-01 → 2024-03-31Cons.Operating income
Operating income¥1.3bn2022-04-01 → 2023-03-31Cons.Operating income
Ordinary income¥636m2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥918m2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥636m2023-04-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥1.2bn2022-04-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥385m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥830m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥588m2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥385m2023-04-01 → 2024-03-31Cons.Profit loss
Net income¥830m2022-04-01 → 2023-03-31Cons.Profit loss
Total assets¥6.6bnat 2024-03-31Cons.Assets
Total assets¥6.1bnat 2023-03-31Cons.Assets
Total assets¥5.6bnat 2022-03-31dCons.Total assets (5-year summary)
Total liabilities¥3.2bnat 2024-03-31Cons.Liabilities
Total liabilities¥3.1bnat 2023-03-31Cons.Liabilities
Net assets / equity¥3.3bnat 2024-03-31Cons.Net assets
Net assets / equity¥3.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥2.2bnat 2022-03-31dCons.Net assets
Cash and deposits¥1.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥1.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥1.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.7bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥824m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥461m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥763m2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥577m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥575m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥83m2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥1m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥172m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥360m2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥92.432023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥199.232022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥173.52021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥802.5at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥724.57at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥532.27at 2022-03-31dCons.Net assets per share (5-year summary)
Equity ratio50.7%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio49.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.6%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
ROE12.1%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE31.7%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE31.2%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
Employees159at 2024-03-31Cons.Number of employees
Employees139at 2023-03-31Cons.Number of employees
Employees130at 2022-03-31dCons.Number of employees
Revenue¥4.4bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥4.4bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥3.6bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥3.3bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥2.8bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥445m2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥1.1bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥409m2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥1.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥842m2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥666m2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥456m2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥423m2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥1.1bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥212m2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥751m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥564m2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥685m2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥303m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥6.0bnat 2024-03-31StandaloneAssets
Total assets¥5.8bnat 2023-03-31StandaloneAssets
Total assets¥5.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥4.8bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥4.2bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥3.2bnat 2024-03-31StandaloneLiabilities
Total liabilities¥3.0bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥2.8bnat 2024-03-31StandaloneNet assets
Net assets / equity¥2.7bnat 2023-03-31StandaloneNet assets
Net assets / equity¥2.0bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥1.4bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥748mat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥1.0bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥50.92023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥180.372022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥166.592021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥2,023.852020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥896.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥142023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥192022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1002020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥452019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥683.18at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥651.21at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥480.9at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,121.96at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,105.69at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio47.2%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio47.2%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio38.0%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio28.9%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio17.3%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE7.6%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE31.9%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE33.2%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE64.7%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE54.7%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued4,165,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued4,165,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued416,500at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued338,500at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued338,500at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees135at 2024-03-31StandaloneNumber of employees
Employees117at 2023-03-31StandaloneNumber of employees
Employees108at 2022-03-31dStandaloneNumber of employees
Employees98at 2021-03-31dStandaloneNumber of employees
Employees101at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 42
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2023-04-01 → 2024-03-31¥15m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥415m
Cell Process Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥114m
Cell Process Businessreportable segmentemployeesat 2024-03-3136 pure
Cell Process Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.2bn
Cell Process Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥1.2bn
Cell Process Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥472m
Microbiological Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥100m
Microbiological Businessreportable segmentemployeesat 2024-03-3150 pure
Microbiological Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.7bn
Microbiological Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥1.7bn
Microbiological Businessreportable segmentsegment profit2023-04-01 → 2024-03-31−¥69m
Tissue Culture Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥69m
Tissue Culture Businessreportable segmentemployeesat 2024-03-3159 pure
Tissue Culture Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.9bn
Tissue Culture Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥1.9bn
Tissue Culture Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥609m
—segment totaldepreciation2023-04-01 → 2024-03-31¥284m
—segment totalrevenue2023-04-01 → 2024-03-31¥4.8bn
—segment totalrevenue external2023-04-01 → 2024-03-31¥4.8bn
—segment totalsegment profit2023-04-01 → 2024-03-31¥1.0bn
Reconciling Itemsreconcilingdepreciation2022-04-01 → 2023-03-31¥13m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥353m
Cell Process Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥20m
Cell Process Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥697m
Cell Process Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥697m
Cell Process Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥281m
Microbiological Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥85m
Microbiological Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥2.4bn
Microbiological Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥2.4bn
Microbiological Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥818m
Tissue Culture Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥46m
Tissue Culture Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥1.6bn
Tissue Culture Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥1.6bn
Tissue Culture Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥522m
—segment totaldepreciation2022-04-01 → 2023-03-31¥151m
—segment totalrevenue2022-04-01 → 2023-03-31¥4.7bn
—segment totalrevenue external2022-04-01 → 2023-03-31¥4.7bn
—segment totalsegment profit2022-04-01 → 2023-03-31¥1.6bn
Cell Process Businessreportable segmentemployeesat 2024-03-3136 pure
Microbiological Businessreportable segmentemployeesat 2024-03-3145 pure
Tissue Culture Businessreportable segmentemployeesat 2024-03-3140 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,335
ItemContextValueUnit
Shareholding ratioCurrentYearInstant_No2MajorShareholdersMember0.1000
Number of shares heldCurrentYearInstant_No3MajorShareholdersMember270000
Shareholding ratioCurrentYearInstant_No3MajorShareholdersMember0.0648
Number of shares heldCurrentYearInstant_No4MajorShareholdersMember176000
Shareholding ratioCurrentYearInstant_No4MajorShareholdersMember0.0423
Number of shares heldCurrentYearInstant_No5MajorShareholdersMember140000
Shareholding ratioCurrentYearInstant_No5MajorShareholdersMember0.0336
Number of shares heldCurrentYearInstant_No6MajorShareholdersMember120000
Shareholding ratioCurrentYearInstant_No6MajorShareholdersMember0.0288
Number of shares heldCurrentYearInstant_No7MajorShareholdersMember100000
Shareholding ratioCurrentYearInstant_No7MajorShareholdersMember0.0240
Number of shares heldCurrentYearInstant_No8MajorShareholdersMember100000
Shareholding ratioCurrentYearInstant_No8MajorShareholdersMember0.0240
Number of shares heldCurrentYearInstant_No9MajorShareholdersMember100000
Shareholding ratioCurrentYearInstant_No9MajorShareholdersMember0.0240
Number of shares heldCurrentYearInstant_No10MajorShareholdersMember80000
Shareholding ratioCurrentYearInstant_No10MajorShareholdersMember0.0192
Number of shares heldCurrentYearInstant3712000
Shareholding ratioCurrentYearInstant0.8912
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of voting rights issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember－
Number of voting rights issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember41650
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember4165000
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember－
Number of shares issued shares voting rightsCurrentYearInstant4165000
Number of voting rights issued shares voting rightsCurrentYearInstant41650
Total amount of dividends dividends of surplusFilingDateInstant_Row1Member58310000JPY
Dividend per share dividends of surplusFilingDateInstant_Row1Member14.00
Number of male directors and other officersFilingDateInstant9
Number of female directors and other officersFilingDateInstant0
Ratio of female directors and other officersFilingDateInstant－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraTakahitoMember2626000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000NakamuraYuichiMember53000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000TsuihijiHisayoshiMember15000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000HaraMinoruMember10000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000MizukamiAkihiroMember3000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000YamamotoRyotaroMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000MorikaneYasuhiroMember3000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000HirosawaKazuhiroMember3000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E38689-000UmetsuHideakiMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant2713000
Audit fees reporting companyPrior1YearDuration47750000JPY
Non audit fees reporting companyPrior1YearDuration－JPY
Audit fees reporting companyCurrentYearDuration48635000JPY
Non audit fees reporting companyCurrentYearDuration3570000JPY
Audit fees consolidated subsidiariesPrior1YearDuration－JPY
Non audit fees consolidated subsidiariesPrior1YearDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass